BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15564451)

  • 1. Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain.
    Ye L; Bu Z; Vzorov A; Taylor D; Compans RW; Yang C
    J Virol; 2004 Dec; 78(24):13409-19. PubMed ID: 15564451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of immunogenicity of an HIV Env DNA vaccine by mutation of the Tyr-based endocytosis motif in the cytoplasmic domain.
    Bu Z; Ye L; Vzorov A; Taylor D; Compans RW; Yang C
    Virology; 2004 Oct; 328(1):62-73. PubMed ID: 15380359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
    Quiñones-Kochs MI; Buonocore L; Rose JK
    J Virol; 2002 May; 76(9):4199-211. PubMed ID: 11932385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct.
    Kumar S; Yan J; Muthumani K; Ramanathan MP; Yoon H; Pavlakis GN; Felber BK; Sidhu M; Boyer JD; Weiner DB
    DNA Cell Biol; 2006 Jul; 25(7):383-92. PubMed ID: 16848679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
    Akahata W; Yang ZY; Nabel GJ
    J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins.
    Berlioz-Torrent C; Shacklett BL; Erdtmann L; Delamarre L; Bouchaert I; Sonigo P; Dokhelar MC; Benarous R
    J Virol; 1999 Feb; 73(2):1350-61. PubMed ID: 9882340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release.
    Noble B; Abada P; Nunez-Iglesias J; Cannon PM
    J Virol; 2006 Mar; 80(6):2924-32. PubMed ID: 16501101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter].
    Wyss S; Berlioz-Torrent C; Boge M; Blot G; Höning S; Benarous R; Thali M
    J Virol; 2001 Mar; 75(6):2982-92. PubMed ID: 11222723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.
    Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS
    Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions.
    Johnson JE; Rodgers W; Rose JK
    Virology; 1998 Nov; 251(2):244-52. PubMed ID: 9837788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
    Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct interaction between the envelope and matrix proteins of HIV-1.
    Cosson P
    EMBO J; 1996 Nov; 15(21):5783-8. PubMed ID: 8918455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
    Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses.
    Gzyl J; Bolesta E; Wierzbicki A; Kmieciak D; Naito T; Honda M; Komuro K; Kaneko Y; Kozbor D
    Virology; 2004 Jan; 318(2):493-506. PubMed ID: 14972518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions.
    Katz E; Moss B
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1497-500. PubMed ID: 9390748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stable expression of the human immunodeficiency virus type 1 envelope glycoprotein in transfected L cells.
    Bird C; Gleeson PA; Ramsay A; Li P; McCluskey J
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):1999-2009. PubMed ID: 1493050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
    Lu S; Wyatt R; Richmond JF; Mustafa F; Wang S; Weng J; Montefiori DC; Sodroski J; Robinson HL
    AIDS Res Hum Retroviruses; 1998 Jan; 14(2):151-5. PubMed ID: 9462925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.